XML 90 R73.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events (Details)
 1 Months Ended 12 Months Ended
May 11, 2022
USD ($)
$ / shares
shares
Apr. 16, 2022
$ / shares
shares
Mar. 31, 2022
USD ($)
shares
Dec. 31, 2021
Jan. 31, 2022
shares
Subsequent Events (Details) [Line Items]          
Terms of agreement, description       In accordance with the terms of the Agreement, the Company shall pay BioLite (i) milestone payments of up to $100 million in cash and equity of the Company or equity securities owned by it at various stages on a schedule dictated by BioLite’s achievements of certain milestones, as set forth in the Agreement (the “Milestone Payments”) and (ii) a royalty payment equal to 5% of net sales of the drug products when ABV-1501 is approved for sale in the licensed territories.  
Milestone payment, description       According to the Agreement, after Phase II clinical trials are completed, 15% of the Milestone Payment becomes due and shall be paid in two stages: (i) 5% no later than December 31, 2021 (the “December 2021 Payment”) and (ii) 10% no later than December 31, 2022. On February 12, 2022, the Company’s Board of Directors determined that the December 2021 Payment, which is equal to $5,000,000, shall be paid via the cancellation of certain outstanding debt, in the amount of $5,000,000, that BioLite owes the Company as of December 31, 2021.  
Aggregated shares of common stock         1,306,007
Additional shares of common stock     75,000    
Consulting and advisory services (in Dollars) | $     $ 15,000    
Subsequent Event [Member]          
Subsequent Events (Details) [Line Items]          
Number of directors   5      
Granted options to purchase an aggregate shares   761,920      
Exercise price per share (in Dollars per share) | $ / shares   $ 3      
Grant date term   10 years      
Purchase agreement relating to offer and sale of shares 2,000,000        
Common stock, par value (in Dollars) | $ $ 0.001        
Warrants purchased 2,000,000        
Exercisable price per share (in Dollars per share) | $ / shares $ 2.45